Compare Dishman Pharma with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs FULFORD INDIA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA FULFORD INDIA DISHMAN PHARMA/
FULFORD INDIA
 
P/E (TTM) x 25.1 398.8 6.3% View Chart
P/BV x 3.3 6.2 53.9% View Chart
Dividend Yield % 0.7 0.1 784.6%  

Financials

 DISHMAN PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
FULFORD INDIA
Mar-14
DISHMAN PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs374942 39.7%   
Low Rs129450 28.6%   
Sales per share (Unadj.) Rs197.8691.4 28.6%  
Earnings per share (Unadj.) Rs21.211.5 185.0%  
Cash flow per share (Unadj.) Rs34.715.4 226.1%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.3 276.6%  
Book value per share (Unadj.) Rs179.9380.0 47.3%  
Shares outstanding (eoy) m80.693.90 2,069.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.0 126.4%   
Avg P/E ratio x11.960.7 19.5%  
P/CF ratio (eoy) x7.245.3 16.0%  
Price / Book Value ratio x1.41.8 76.4%  
Dividend payout %9.417.4 54.0%   
Avg Mkt Cap Rs m20,3062,714 748.1%   
No. of employees `0000.80.4 186.7%   
Total wages/salary Rs m5,355505 1,060.4%   
Avg. sales/employee Rs Th19,252.76,073.0 317.0%   
Avg. wages/employee Rs Th6,459.51,137.4 567.9%   
Avg. net profit/employee Rs Th2,064.1100.7 2,050.2%   
INCOME DATA
Net Sales Rs m15,9612,696 591.9%  
Other income Rs m265125 211.6%   
Total revenues Rs m16,2262,822 575.0%   
Gross profit Rs m4,103-46 -8,843.1%  
Depreciation Rs m1,09115 7,175.0%   
Interest Rs m94410 9,941.1%   
Profit before tax Rs m2,33454 4,297.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m62410 6,495.8%   
Profit after tax Rs m1,71145 3,828.0%  
Gross profit margin %25.7-1.7 -1,494.0%  
Effective tax rate %26.717.7 151.2%   
Net profit margin %10.71.7 646.7%  
BALANCE SHEET DATA
Current assets Rs m11,0181,738 633.8%   
Current liabilities Rs m9,517545 1,747.2%   
Net working cap to sales %9.444.3 21.2%  
Current ratio x1.23.2 36.3%  
Inventory Days Days11048 228.0%  
Debtors Days Days354 809.3%  
Net fixed assets Rs m16,30412 137,009.2%   
Share capital Rs m16139 413.8%   
"Free" reserves Rs m12,9071,443 894.4%   
Net worth Rs m14,5161,482 979.5%   
Long term debt Rs m4,1890-   
Total assets Rs m29,8052,077 1,435.2%  
Interest coverage x3.56.7 51.7%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.3 41.2%   
Return on assets %8.92.6 341.4%  
Return on equity %11.83.0 390.8%  
Return on capital %17.54.3 407.2%  
Exports to sales %24.80-   
Imports to sales %3.724.5 15.3%   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596659 90.4%   
Fx inflow Rs m4,95217 28,787.8%   
Fx outflow Rs m697673 103.5%   
Net fx Rs m4,255-656 -648.6%   
CASH FLOW
From Operations Rs m2,78690 3,096.0%  
From Investments Rs m-1,529105 -1,461.7%  
From Financial Activity Rs m-941-14 6,674.5%  
Net Cashflow Rs m316181 175.3%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 3.8 97.4%  
FIIs % 12.7 0.1 12,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 21.2 104.2%  
Shareholders   46,261 4,783 967.2%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON   PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS